Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation reports recurring developments across its global medical technology business, including financial results, investor conference participation, product studies and U.S. regulatory actions. The company’s solutions include hospital technologies, end-to-end plasma collection technologies for plasma centers and products used by blood centers to collect blood components.
Company news frequently centers on the VASCADE MVP and VASCADE MVP XL venous vascular closure systems, the NexSys PCS Plasma Collection System and Persona technology. Updates also cover FDA approvals or 510(k) clearances, clinical evidence supporting device use, earnings releases and presentations, and communications tied to the company’s plasma, blood center and hospital markets.
Haemonetics Corporation (NYSE: HAE) announced it will release its first quarter fiscal year 2022 financial results on August 11, 2021, at 6:00 am EDT. Following this, a conference call will take place at 8:00 am EDT on the same day to discuss the results and answer questions. Investors can access the call via a toll-free number or through an online webcast. A replay will be available for one year starting from August 11, 2021, at 11:00 am EDT.
Haemonetics Corporation (NYSE: HAE) revealed its financial results for the fourth quarter of fiscal 2021, which ended on April 3, 2021. The results can be accessed on the company's Investor Relations website. Following the release, a conference call and webcast will be held on May 13, 2021, at 8:00 a.m. ET, allowing investors to engage with management and learn more about the results. The company’s offerings support healthcare improvements in blood and plasma collection, surgical services, and hospital transfusions. Detailed earnings information is also available through direct links provided in the announcement.
Haemonetics Corporation (NYSE: HAE) announces the publication of full results from the IMPACT trial in the journal TRANSFUSION. This multicenter study analyzed plasma collection methods involving 3,443 donors and 23,137 donations. The trial compared NexSys PCS® with YES® Technology and its Persona® Technology, achieving an 8.2% increase in plasma yield without compromising safety. The NexSys PCS® system with Persona® received FDA clearance in 2020. Plasma is vital for therapies for conditions like hemophilia and primary immunodeficiency, affecting approximately 750,000 patients across North America and Europe.
Haemonetics Corporation (NYSE: HAE) will release its fourth quarter and fiscal year 2021 financial results on May 13, 2021, at 6:00 am EDT. An investor conference call will follow at 8:00 am EDT to discuss the results. Interested participants can join the call via a toll-free number for U.S. and Canada or an international line, with a required conference ID of 8694785. A live webcast will also be available on the company's investor relations website, and a replay will be accessible for one year starting at 11:00 am EDT on the same day.
Haemonetics Corporation (NYSE: HAE) announced that CSL Plasma will not renew their Supply Agreement for PCS2® Plasma Collection System devices in the U.S., effective June 2022. This decision, driven by CSL's internal strategy, will affect approximately $117 million in revenue, which is 11.8% of Haemonetics' total revenue. The company anticipates a $25 million impairment charge and an additional $7 million in expenses in Q4 FY2021. Despite this, Haemonetics remains committed to supporting CSL in other markets and expects continued growth in U.S. plasma collections.
Haemonetics Corporation (NYSE: HAE) has priced a private offering of $435 million aggregate principal amount of 0.00% Convertible Senior Notes due March 2026. This offering, increased from a previous $425 million, is set to close on March 5, 2021. The notes will not bear regular interest and are convertible into common stock at an initial price of approximately $175.34, a 40% premium over the last reported sale. Haemonetics estimates net proceeds of about $423.3 million, for debt reduction and other corporate purposes.
Haemonetics Corporation (NYSE: HAE) announced a private offering of $425 million in Convertible Senior Notes due 2026. The offering is subject to market conditions and is targeted at qualified institutional buyers. An additional $63.75 million may also be offered. The notes will be unsecured and allow conversion into cash or stock. Proceeds will be used for capped call transactions and to reduce existing debt. However, there are risks associated with market conditions and the effectiveness of the capped call transactions.
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, the President and CEO, will present at the Jefferies Plasma Summit on March 11, 2021, at 10:45 a.m. ET. The presentation will be accessible live via webcast, with a replay available for one month. Haemonetics is focused on delivering innovative medical products and solutions, primarily in blood and plasma collection, surgical services, and hospital transfusions.
Haemonetics Corporation (NYSE: HAE) announced the availability of its third-quarter fiscal 2021 financial results, concluding on December 26, 2020. A conference call is scheduled for February 2, 2021, at 8:00 a.m. ET, to discuss the results and address investor queries. The earnings release, analytical tables, and details regarding the acquisition of Cardiva Medical, Inc. have been posted on the Investor Relations website. The company's innovative healthcare solutions aim to enhance patient care while reducing healthcare costs.
Haemonetics Corporation (NYSE: HAE) supports the FDA's new guidance on viscoelastic testing during the COVID-19 pandemic. The company is modifying labeling for its TEG® 5000 and TEG® 6s hemostasis analyzers to enhance patient care. These analyzers provide critical insights into blood clotting, addressing coagulopathy associated with COVID-19, which can lead to severe complications. Haemonetics aims to optimize blood resource utilization while ensuring that healthcare professionals have access to necessary technologies during this crisis.